

State of Oklahoma SoonerCare Padcev[®] (Enfortumab Vedotin-ejfv) Prior Authorization Form

M	ember Name:	Date of Birth:		
Drug Information				
□Physician billing (HCPCS code:) □Pharmacy billi) □Pharmacy billing (NDC:)	
Dose: Regimen:		en: Start Da	Start Date (or date of next dose):	
Billing Provider Information				
Provider NPI:		Provider Name:	Provider Name:	
Provider Phone:		Provider Fax:	Provider Fax:	
Prescriber Information				
Prescriber NPI: Prescriber Name:				
Prescriber Phone:		Prescriber Fax:	Specialty:	
Criteria				
For Initial Authorization: 1. Is diagnosis locally advanced or metastatic urothelial cancer? Yes No 2. Has the member previously received a programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting? Yes No 3. Has the member received at least 1 prior therapy? Yes No 4. Is the member eligible for cisplatin-containing chemotherapy? Yes No 5. If diagnosis is NOT locally advanced or metastatic urothelial cancer, please indicate diagnosis: Additional Information: For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on enfortumab vedotin therapy? Yes No 3. Has member experienced any adverse drug reactions related to enfortumab vedotin therapy? Yes No 1. If yes, please specify adverse reactions: Additional Information:				
	escriber Signature:	Da ^a	te:	
		ent is medically necessary and all complete this form in full will result in	information is true and correct to the	

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 145 11/21/2022